K turns and outweighs the entire aff
Phillips, 20 (Leigh Phillips is a science writer and EU affairs journalist., 12-22-2020, accessed on 3-9-2021, Jacobinmag, "Thank Socialism for the Vaccine. Blame Capitalism for Its Distribution.", https://jacobinmag.com/2020/12/socialism-vaccine-capitalism-distribution)
The jaw-dropping speed of COVID-19 vaccine development is a glorious marvel of science, cooperation, and economic planning — a glimpse of how much more an egalitarian world could produce and achieve. But the lifeboat ethics of vaccine rollout is a horrifying display of the inefficiency and cruelty of capitalism. A medical professional prepares to administer a vaccine. (Wikipedia Commons) Our new issue, “Biden Our Time,” is out now. We discuss the last four chaotic years of US politics, what happened in November, and what to expect from the Biden administration. Get a $20 discounted print subscription today! This article is a preview from a forthcoming print issue of Jacobin. Just for the holidays, subscribe to a year of our quarterly magazine for just $12. When nurse May Parsons administered the first injection in the world of the Pfizer-BioNTech COVID-19 vaccine to ninety-year-old British grandmother Margaret Keenan, applauded by dozens of moist-eyed medical staff at University Hospital Coventry, it was as glorious and moving a moment as any humanity has ever seen. A jaw-dropping marvel of science, economic planning, and selfless, humanist cooperation by thousands of researchers around the globe, the development of this and other vaccines hot on Pfizer’s heels has taken a mere nine months since the discovery of the disease, rather than the years or even decades such medical research and development (R&D) normally takes. They offer a glimpse of how much more an egalitarian, rationalist world could produce and achieve, freed from the fetters of profit. While the American private pharmaceutical giant and its German biotech start-up partner may bear the name of the first vaccine, this is no triumph for capitalism. Pfizer-BioNTech, along with the second-place finisher, Moderna, and the other front-runners, all depended on years of public-sector funding for their success, and, in many cases, on research actually performed by government or public university labs long before 2020. And again during this plague year, these private companies relied on state shepherding and bankrolling of the vaccine development process or, in the case of Pfizer, state-guaranteed purchase of millions of doses. In many cases, national governments arranged purchase agreements and manufacturing support ahead of clinical trial results so that rollout could start as soon as regulatory approval was given, rather than having to wait for approval before manufacture could begin. Washington promised to purchase some $2 billion worth of the Pfizer vaccine and guaranteed about $2.5 billion to Moderna for the development and manufacture of its option. The incredible speed of vaccine development just about makes up for the all-too-predictable news that the head of Pfizer cashed out 62 percent of his stock on the same day the company released the results of its vaccine trial showing 90 percent–plus efficacy, and that executives at Moderna made similar moves after their own announcement. In both cases, the stock sale occurred through what the firms insist was an entirely by the book, prearranged application of Rule 10b5-1, which insider trading law permits. But, as NPR has reported, experts in insider trading ethics say this is the thinnest of defenses of what is “very suspicious” or even “wholly inappropriate” behavior. Even if we are gullibly charitable in our assessment of the ethics of these moves, strategically, they remain profoundly stupid, given the scale of vaccine hesitancy. It is not enough to be ethical; one must be seen to be ethical as well. So, to even appear to be engaging in insider trading with respect to vaccine development is a gift to anti-vax campaigners and COVID conspiracists. Such insider trading ethical fiascos aside, the rapid development of the vaccine has stunned experts. They knew more than anyone how long it normally takes for vaccine development. For years, these same infectious disease researchers, clinicians, and public health officials have damned the pharmaceutical giants for largely getting out of the business of vaccine development several decades ago. Contrary to anti-vax legend, pharmaceutical companies are, in reality, loath to engage in vaccine production because of the financial risk involved and their sheer unprofitability. Now, suddenly, in the face of a nigh-on existential threat, when the state bashes CEO heads together and takes on all financial risk, vaccines of stunning efficacy appear after just months. It is almost identical to what happened during World War II, when the US government, frustrated with the intransigence of chemical companies and nascent pharmaceutical firms again fearing lack of profitability, simply ordered cooperation across enterprises, made investment decisions on behalf of the private sector, and covered the costs of research, development, and manufacturing. The result was the development or improvement of ten vaccines of military significance. The same wartime planning efforts produced the mass rollout of the first antibiotic, penicillin. Moving forward, these lessons show that the inefficiencies of the market must now permanently be done away with for vaccine development related to all other infectious diseases that suffer from a dearth of private R&D. For tuberculosis, for example, we have only a feeble, century-old vaccine that ameliorates the problem but is insufficient to prevent deaths from TB each year equivalent to those killed by COVID-19. In 2020, COVID killed 1.7 million worldwide; in 2019, TB killed 1.4 million. But before we get out the champagne and toast our genuinely heroic scientists and clinicians, we have to recognize that while these vaccines are indeed a light at the end of a very long tunnel, that same tunnel will be yet longer than it needs to be, thanks once again to the irrationality, inefficiency, and injustice of capitalism. It will be especially unfair for those in the developing world — and even in many poorer, less populous parts of the developed West, there will be cruelties for those who live outside the metropolitan core, as there already have been throughout 2020 in the United States especially. In the spring, stories abounded of testing, PPE, and ventilation machines being distributed on the basis of who could pay the most rather than who needed them the most. Even Republican governors of small states were fuming at how orders, paid in full, for essential equipment were canceled — sometimes mid-shipment — so as to make more money servicing richer jurisdictions. An almost identical crime is already in progress once again, but this time with respect to the logistics of vaccine manufacture and distribution. To explain the profound injustice and hair-pulling inefficiencies of what is about to happen with respect to the domestic and worldwide distribution of the COVID-19 vaccines, we need to take a brief detour to explain how these vaccines work — in particular, how the ones first out of the gate are very different, even revolutionary, compared to other vaccines. Conventional vaccines work essentially the same way they did upon their discovery in the days of Louis Pasteur. Inoculation involves exposure to a weakened or killed virus, which thus presents to the immune system an antigen — a molecular structure that is part of a pathogen that prompts an immune system response. The antigen we are focused on, with respect to the SARS-CoV-2 virus that causes COVID-19, is the infamous “spike” protein that covers its surface. The immune system then is able to remember and recognize any “live” version of the pathogen if, in the future, it attempts to invade the body. Now the immune system has a ready-prepared capability of combating and defeating it. Depending on the virus, this protection can last for life, a few years, or even a few months — hence the need for booster shots for some vaccines. Traditional vaccines have been around for well over a century, and so the technology is mature and the manufacturing process is well established — even if the supply chain is somewhat withered due to the aforementioned decades-long retreat by Big Pharma from not just vaccine R&D but also vaccine production. The major challenge with respect to rapid rollout of traditional vaccines is that they need to be “grown” in hens’ eggs or insect cells. Each batch takes several weeks. There are eight main vaccine techniques, including a handful of traditional, weakened virus versions, among the roughly two hundred candidate COVID vaccines currently at various stages of development (there are fifty-seven presently undergoing clinical trials). Right now, the Pfizer-BioNTech and Moderna vaccines are of most immediate interest and are the most exciting in terms of the possibility that they may revolutionize vaccine production. They are messenger RNA, or mRNA, vaccines, the concept of which has been in development for many years — funded primarily by, you won’t be surprised to hear by now, the public sector. (The Oxford-AstraZeneca vaccine uses a different method, or “molecular platform” — more on this shortly.) Messenger RNA, as you might remember from high school biology, is the molecule that transcribes the instructions in your DNA. This transcription is then read by ribosomes, the little machines in your cells that use these transcribed instructions to manufacture the proteins that make up almost everything in your body. With mRNA vaccines, instead of presenting the immune system with a whole virus, which has taken weeks to grow in hens’ eggs, just this bit of mRNA, embedded in a lipid nanoparticle (a fat molecule that helps it enter a cell) with the instructions on how to manufacture a viral antigen, is injected into the body. The mRNA then directs the cell’s ribosome protein factories to produce copies of the antigen (the spike, in this case), sans virus. The immune system recognizes the spikes as foreign and attacks them, then subsequently remembers how to attack when confronted with the real thing. It’s very clever on a number of levels. Far smaller doses are required to prompt an immune response, which means greater quantities can be produced much more rapidly than traditional vaccines. Also, once the genetic sequence for an antigen protein is known, you can quickly repurpose the same manufacturing equipment — bioreactors — for this new antigen. Conventional vaccine manufacture, meanwhile, requires slightly different bespoke equipment each time. The mRNA molecular platform had already been developed well ahead of the COVID-19 pandemic, which meant that as soon as the gene sequence for the spike was identified, which happened within days of the disease’s discovery, the vaccine could immediately start being produced. What took time was the clinical trials, and to speed them up, the different phases of the trials were performed in parallel instead of sequentially, as is normal practice. This is the reason vaccine development has been so fast. In the future, when confronted with other outbreaks of novel viruses, so long as we have set up the mRNA production equipment ahead of time, ready to go, we can simply fire them up with the new antigen genetic sequence. As it may be a long time between outbreaks, without any opportunity for profit, such facilities will likely need to be maintained or at least funded by the state simply as a public service, like sewage systems or, more analogously, like fire brigades, paid primarily to just be there, ready for when the emergency comes. The downside is that while some other types of vaccine can be kept stable in regular refrigerators, the lipid nanoparticle vehicles for the mRNA need to be kept ultracold to avoid breaking down. The mRNA molecule likewise begins to fall apart at room temperature. The Pfizer-BioNTech vaccine requires refrigerators that can keep the combo at a cozy -70ºC (-94ºF). And this, what is called a “cold chain” — a low-temperature-sensitive supply chain — is where we confront just the first in a series of hurdles to efficient and fair rollout of the vaccines that are caused by or exacerbated by market irrationality. Food distribution worldwide already depends on a highly developed cold chain, but an ultracold chain, with the sort of temperatures the Pfizer vaccine requires, is a step beyond that. It’s common for research labs to have freezers that can keep things that cold, but not the pharmacies where, for example, you might have received a flu shot. Pfizer is shipping the vaccine in dry ice pack boxes. Once received, the dry ice needs to be replenished within a day. Once taken out of the dry ice pack boxes, the vaccine can be kept at regular refrigerator temperatures for twenty-four hours, or a maximum of two hours once thawed at room temperature. Ultracold freezers can extend shelf life by six months and are, in principle, commercially available. As a result, major hospitals in metropolitan areas are running around trying to get their hands on these very cold but also very expensive freezers (which cost $10–15,000 a pop). And much like the hunt for personal protective equipment (PPE) and ventilation machines in the spring, a disorganized every-man-for-himself approach has returned in the winter. Rural areas and towns with smaller populations are being trampled in the stampede. The pandemic has bludgeoned the finances of less well-off hospitals, and these are expenditures they often just cannot afford. Even those hospitals that could afford one or two freezers are being told by manufacturers that delivery will take months; wealthier, larger hospitals that are able to buy in bulk get priority.